St. Félicien, Quebec, February 21, 2017. Axcelon Biopolymers Corp. (ABC) announced today that it is contemplating building its demonstration bacterial nanocellulose (BNC) production facility in St. Félicien, Qc. The project will incorporate ABC’s proprietary BNC organism to produce high value bioproducts for wound care, medical devices, and industrial sectors.
Dino Mili, ABC’s president indicated; “ABC is focused on becoming a leader in the production of BNC where there is a growing need for green polymers that are biosourced and biodegradable to replace petroleum based products.” ABC’s first product to market is Nanoderm®, a unique a one-time application woundcare product that provides a barrier to infections and helps alleviate pain. ABC has other patents related to the medical devices field in development as well working to use BNC in 3-D printing and electro-spinning applications for the production of biocomposites of superior performance as compared to non-bio alternatives.
Mr. Gilles Potvin, Mayor of St. Felicien indicated that; “We are excited to work with Axcelon to establish its feasibility production plant in St. Félicien’s industrial park. This is a very exciting platform technology that will provide opportunities to develop expertise in the growing biomaterials sector.” The project will be located in the industrial park where it will use waste “warm water” energy that is rejected from a biomass power plant which will reduce operating costs. The ability to integrate with a biomass power plant will also significantly reduce ABC’s GHG footprint and improve the energy efficiency of the power plant.
About Axcelon Biopolymers Corp.
Axcelon Biopolymers Corp. is a private company developing and commercializing bacterial nanocellulose based products for biomedical devices as well as for non-medical applications. The company has several proprietary assets for development of advanced wound-care products, cardiovascular grafts, tympanic membrane as well as other high value consumer products. Axcelon maintains key operations in Toronto, London, Ontario as well as Montreal.
Contact information: Dino Mili, president; firstname.lastname@example.org
Tel: 514 371 9676
This news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks.